ArticleFrontiers in medicine2025
Identification and validation of mitochondria-related genes in panvascular diseases.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Panvascular diseases represent a spectrum of vascular conditions where atherosclerosis plays a central role in the pathophysiology. This study focused on identifying differentially expressed genes (DEGs) related to mitochondria and key genes associated with peripheral artery disease (PAD) and coronary artery disease (CAD). This study identified MPV17 as a key mitochondrial gene bridging peripheral artery disease (PAD) and coronary artery disease (CAD). Analysis of GEO datasets revealed differentially expressed mitochondrial genes, with MPV17, FADD, HLCS, and PEX3 highlighted. A diagnostic nomogram, developed using LASSO and Random Forest methods, demonstrated high accuracy in predicting PAD and CAD (AUC >0.93). Furthermore, the study revealed significant alterations in immune cell infiltration associated with both diseases, suggesting a potential role for immune modulation in panvascular disease. MPV17 shows promise as a diagnostic marker for early identification and differentiation of these vascular conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.